Best Life Sciences Companies in Pasadena, United States
The 41 best Life Sciences companies in Pasadena, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Arrowhead Pharmaceuticals.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Pasadena
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Arrowhead Pharmaceuticals Developer of therapeutics to treat multiple diseases | $290M | 15 mo ago | Acquired | 427 427 → 809 (+89%) | Christopher Anzalone CEO & President | 1,202 patents RNAi therapeutics and targeted antibody/lipid conjugates for disease gene silencing | — |
| 2 | Terray Provider of AI-based drug candidate identification solutions for drug development | $200M | 22 mo ago | Series B | 50 | — | — | 1 launch · 1 award |
| 3 | Spatial Genomics Developer of multiplexed assays for drug development 24Moat top 22%Funding top 32%Talent bottom 49%Tech bottom 47% All 6 signals ▾Moattop 22% Fundingtop 32% Talentbottom 49% Techbottom 47% Globalbottom 32% Marketbottom 29% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $56.0M across 7 rounds · 7 rounds over 4 yrs (1.8/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $56M | 15 mo ago | Series A | 21 | Drew Kennedy Co-Founder | — | — |
| 4 | Promis Diagnostics Developer of non-invasive diagnostics for screening colon cancer | $41M | 79 mo ago | Series A | 9 | — | — | — |
| 5 | Amicrobe Innovating large molecule biologics for diverse industries, promoting health and environmental benefits | $23M | 75 mo ago | Series B | 12 | Timothy Deming Co-Founder | 75 patents Topical antimicrobial peptide coatings for medical devices and wound care | — |
| 6 | Deep 6 AI AI enabled solutions for clinical trials | $22M | 52 mo ago | Acquired | 41 | — | 47 patents AI-driven biomedical data mining, signal intelligence, and event detection using neural networks. | — |
| 7 | BioVinc Proprietary chemistry to target imaging probes and pharmaceutical agents to bone tissue | $16M | 17 mo ago | Funding Raised | 7 | — | 22 patents Patents concentrated in health & consumer products | — |
| 8 | Replenish Implantable ocular drug pump to treat ophthalmic diseases in the posterior chamber | $10M | 205 mo ago | Series A | 2 | Sean Caffey Co-Founder & CEO | 9 patents Smart implantable drug‑delivery pumps with modular microfluidics and vented refill mechanisms | — |
| 9 | Neumedicines Clinical-stage biopharmaceutical firm pioneering cancer immunotherapeutics by linking hematopoiesis with… | $9M | 80 mo ago | Funding Raised | 16 | Lena Basile Founder & CEO | 81 patents IL-12 cytokine formulations for hematopoietic recovery and immunotherapy | — |
| 10 | BCN Biosciences Oncology drug discovery, developing novel medicines for cancer prevention and treatment | $8M | 37 mo ago | Funding Raised | 6 | Sudip Chakrabortty Cofounder & CEO | 37 patents Small-molecule therapeutics targeting GSK3β/β‑catenin signaling for cancer treatment | — |
| 11 | Protabit Developing design software tools for engineering proteins | $6M | 75 mo ago | Funding Raised | 6 | Barry Olafson CEO | 6 patents COVID-19 neutralizing antibodies, AI-driven protein engineering platforms, methane‑oxidizing biocatalysts | — |
| 12 | Meditope Developing next-generation oncology therapeutics through innovative meditope-based platform | $5M | 130 mo ago | Series A | 6 | Stephanie Hsieh President and CEO | — | — |
| 13 | GI Logic Innovative gastrointestinal health solutions through wearable biosensors and advanced technology | $4M | 123 mo ago | Series A | — | James Beeton Co-Founder & Co-CEO | — | — |
| 14 | Advanced Telesensors Contactless vital signs detection | $3M | 86 mo ago | Series A | — | Sajol Ghoshal CEO | — | — |
| 15 | Deton Corp Develops sample collection system | $600K | 101 mo ago | Deadpooled | — | Ramzi Nasr Co-Founder & VP | 9 patents Airborne bacterial detection and breath analysis technologies for health diagnostics | — |
| 16 | Proteris Biotech Developing innovative solutions for dry eye disease and corneal disorders | $574K | 35 mo ago | Funding Raised | — | John Fini CoFounder & CEO | — | — |
| 17 | Epicenter Software Genetic data analysis solutions | $300K | 217 mo ago | Deadpooled | — | Jonathan Buckley Founder & President | — | — |
| 18 | eDNA Biotech Provider of portable on-site bacterial testing solutions | $275K | 42 mo ago | Funding Raised | — | Di Kang Founder & CEO | — | — |
| 19 | Ureka Science Collaboration platform for scientists | $150K | 104 mo ago | Deadpooled | — | A Cooray Co-Founder | — | — |
Top 12 Life Sciences companies in Pasadena
#1
Acquired · Pasadena, California · founded 1989 · 427 employees$290.2Mraised▾
Developer of therapeutics to treat multiple diseases. The company develops medicines that treat intractable diseases by silencing the genes that cause them. The company’s pipeline includes ARO-AAT to treat liver diseases, ARO-APOC3 for Hypertriglyceridemia, ARO-ANG3 for Dyslipidemia, and more.
- May 2025Grant (prize money)$305K
- Dec 2017Post IPO$7.2M
- Jan 2017Post IPO$9.7M
- Sep 2016Post IPO$56.5M
#2
Series A · Pasadena, California · founded 2018 · 21 employees$56Mraised▾
Developer of multiplexed assays for drug development. The company develops sequential fluorescence in situ hybridization (seqFISH) an advanced biomolecular analysis method with combinatorial molecular barcoding for fundamental biology, precision medicine, drug development, and diagnostics.http://spatialgenomics.com/
- May 2025Grant (prize money)$1.2M
- Sep 2023Grant (prize money)$2.5M
- Sep 2023Grant (prize money)$2M
- Jun 2023Grant (prize money)$2.7M
#3
Series B · Pasadena, California · founded 2018 · 50 employees$200Mraised▾
Provider of AI-based drug candidate identification solutions for drug development. The platform utilizes AI technology for the prediction and screening of lead candidates for therapeutic purposes. It facilitates rapid identification of small molecules for various targets. The platform supports internal pipeline development and external research collaborations.
- Oct 2024Series B$120M
- Nov 2023Series A—
- Feb 2022Series A$60M
- Seed$20M
#4
Funding Raised · Pasadena, California · founded 2014 · 7 employees$15.5Mraised▾
BioVinc is commercially developing its bone-targeting probes derived from nitrogen-containing bisphosphonates such as risedronate (RIS) and zoledronate (ZOL). The bisphosphonates are conjugated with a wide range of visible and near-infrared fluorescent dyes to address different imaging need for clients.
- Mar 2025Grant (prize money)$2.3M
- Feb 2025Grant (prize money)$2.3M
- Jan 2025Grant (prize money)$2.3M
- Apr 2024Grant (prize money)$1.3M
#5
Funding Raised · Pasadena, California · founded 2006 · 6 employees$7.6Mraised▾
Oncology drug discovery, developing novel medicines for cancer prevention and treatment. This biotechnology corporation focuses on developing and commercializing small molecule and biological therapeutic drug candidates. With an experienced team of drug discovery and oncology experts, the company is committed to creating effective medicines to combat cancer, a significant global health challenge. The company is also actively engaged in developing future products for early-stage cancer detection, paving the way for advancements in this critical area. The company's work aims to bring hope for a healthier world through innovation in oncology.
- Aug 2023Grant (prize money)$2M
- Jul 2019Grant (prize money)$599.5K
- 2014Grant (prize money)$209.2K
- May 2014Grant (prize money)$209.2K
#6
Acquired · Pasadena, California · founded 2013 · 41 employees$21.6Mraised▾
Deep 6 AI (formerly Deep 6 Analytics) develops artificial intelligence enabled solutions for clinical trial use cases. It uses AI technologies to understand the unstructured data from medical records to find more patients for clinical trials easily. It helps hospitals or pharma companies to reduce the onboarding and trail time, reduce record analysis expenses, increase patient outcome, etc.
- Apr 2022Series C$26.9M
- Sep 2019Series B$17.3M
- Nov 2017Series A$5.9M
- Mar 2017Seed—
#7
Series A · Pasadena, California · founded 2019 · 9 employees$40.8Mraised▾
Promisdx is developing non-invasive diagnostic platforms for detecting specific biomarkers for cancer screening. The products developed are a stool-based test used to screen colorectal cancer by identifying biomarker such as DNA methylation and DNA repair genes.
- Jan 2020Series A$10.8M
#8
Series B · Pasadena, California · founded 2010 · 12 employees$22.7Mraised▾
Innovating large molecule biologics for diverse industries, promoting health and environmental benefits. The company designs, patents, and produces macro biologics, focusing on large molecule biologics with enhanced physical properties and functional activities. Their technology aims to create innovative products across multiple industries, offering solutions that are better for both human health and the environment. A lead investigational product, Amicidins, is under development. Select programs receive support from various organizations, including the U.S. Department of Defense and CARB-X. They seek partnerships to create new products and improve existing ones, leveraging their expertise in biologics to address unmet needs. This is a B2B tech company focused on research and development, offering potential social impact through its health and environmental solutions.
- May 2020Series B$16.7M
- Sep 2013Series A$5M
- Feb 2011Seed$1000K
#9
Funding Raised · Pasadena, California · founded 2014$574.5Kraised▾
Developing innovative solutions for dry eye disease and corneal disorders. The company focuses on harnessing the body's natural protective responses for disease prevention and treatment, particularly in ocular health. Their lead product, Protearin™, targets ocular surface damage common in all forms of dry eye by protecting, sealing, and healing. The active ingredient, clusterin, is a natural protein that acts as a molecular chaperone and matrix metalloproteinase inhibitor. Preclinical studies demonstrate that clusterin reduces inflammation, seals damage, restores goblet cells, and regenerates corneal nerves. This research positions Protearin™ as a platform therapy for dry eye and related corneal conditions, offering a potential biological drug for prevention and treatment. The company is involved in pharmaceutical research, drug development, and biotechnology, aiming to provide advanced therapeutic solutions for ocular diseases.
- Sep 2023Grant (prize money)$294.7K
- Feb 2017Grant (prize money)$279.8K
- Apr 2016Grant (prize money)—
#10
Funding Raised · Pasadena, California · founded 2009 · 6 employees$5.9Mraised▾
Developing design software tools for engineering proteins. Its software platform (Triad) integrates computational approaches to protein design with high-throughput screening and directed evolution to expand the diversity of protein sequences that can be explored to produce new and improved proteins. Also, it has Protobank a protein engineering database.
- Jun 2020Grant (prize money)$256K
- Jun 2016Grant (prize money)$2.9M
- Sep 2015Grant (prize money)$750K
- Sep 2015Grant (prize money)$1.3M
#11
Funding Raised · Pasadena, California · founded 2011 · 16 employees$9.1Mraised▾
Clinical-stage biopharmaceutical firm pioneering cancer immunotherapeutics by linking hematopoiesis with immunity. The company is dedicated to breaking oncology immunotherapeutic boundaries through innovative approaches. They focus on linking hematopoiesis with immunity to yield complete and durable responses in cancer treatment. The company is advancing HemaMax, positioned as a combination immunotherapeutic, through clinical trials. A team of research and medical experts leads this clinical advancement. Their work includes research, development, and publication of findings. The company collaborates with other entities to further its mission. They are focused on developing novel therapies for cancer.
- Jan 2020Grant (prize money)$821.4K
- Jun 2013Grant (prize money)$8.3M
#12
Series A · Pasadena, California · founded 2007 · 2 employees$10.2Mraised▾
Manufacturer of a small, automated and refillable ocular drug pump. The company develops a micro-pump system that is implanted under the skin of the eye to deliver nanoliter-sized doses of drugs via a cannula that extends into the anterior chamber of the eye.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.